Knowledge centre

Filter by

Recent posts

Nature Biopharma Dealmakers: Reshaping the production of DNA-based therapies
Nature Biopharma Dealmakers: Reshaping the production of DNA-based therapies
Read more
The Telegraph: UK’s Touchlight to step up DNA production after fundraising
The Telegraph: UK’s Touchlight to step up DNA production after fundraising
Read more
BioProcess International: With $58m in hand, Touchlight looks to triple DNA manufacturing capacity
BioProcess International: With $58m in hand, Touchlight looks to triple DNA manufacturing capacity
Read more
Endpoints News: Synthetic DNA player Touchlight scores $60M round to more than triple manufacturing capacity as mRNA gets hot
Endpoints News: Synthetic DNA player Touchlight scores $60M round to more than triple manufacturing capacity as mRNA gets hot
Read more
Forbes: Meet The UK’s First Synthetic Biology Unicorn
Forbes: Meet The UK’s First Synthetic Biology Unicorn
Read more
STAT Reports: Understanding synthetic biology, featuring 10 companies to watch
STAT Reports: Understanding synthetic biology, featuring 10 companies to watch
Read more
Endpoints Manufacturing: Touchlight’s ‘doggyboneDNA’ looks to rewrite rules of therapeutic DNA
Endpoints Manufacturing: Touchlight’s ‘doggyboneDNA’ looks to rewrite rules of therapeutic DNA
Read more
Careers in Discovery Podcast
Careers in Discovery Podcast
Read more
Labiotech: CDMOs Are the Unsung Heroes of the Gene and Cell Therapy Revolution
Labiotech: CDMOs Are the Unsung Heroes of the Gene and Cell Therapy Revolution
Read more
LDC Most Ambitious Business Leaders of 2020
LDC Most Ambitious Business Leaders of 2020
Read more
BioProcess International: Fallen in place: Lonza veteran to lead Touchlight
BioProcess International: Fallen in place: Lonza veteran to lead Touchlight
Read more
Fierce Pharma: DNA maker Touchlight adds Lonza manufacturing vet as it swings at COVID-19 vaccine, cell and gene therapy markets
Fierce Pharma: DNA maker Touchlight adds Lonza manufacturing vet as it swings at COVID-19 vaccine, cell and gene therapy markets
Read more